α-Klotho prevents diabetic retinopathy by reversing the senescence of macrophages

Qingbo Li1,2,3, Peiyu Wang1,2,3, Yi Gong1,2,3

  • 1Tianjin Key Laboratory of Retinal Functions and Diseases, Eye Institute & School of Optometry and Ophthalmology, Tianjin Medical University Eye Hospital, Nankai District, No. 251, Fukang Road, Tianjin, 300384, China.

PubMed
Abstract

Insights

α-Klotho (KL) alleviates diabetic retinopathy (DR) by reducing macrophage aging and neovascularization. This study shows KL protects against DR by downregulating HECTD1 and decreasing IRS1 ubiquitination.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Immunology

Background:

  • Diabetic retinopathy (DR) is a leading cause of blindness, with aging as a key risk factor.
  • Macrophages in aged individuals exhibit pro-inflammatory profiles, potentially exacerbating DR.
  • The role of α-Klotho (KL), an anti-aging factor, in DR pathophysiology was previously unknown.

Purpose of the Study:

  • To investigate the role of α-Klotho (KL) in diabetic retinopathy (DR).
  • To explore KL's effects on macrophage senescence and neovascularization in diabetes.
  • To elucidate the molecular mechanisms underlying KL's protective effects in DR.

Main Methods:

  • Established type 1 and type 2 diabetic mouse models, and Vldlr-/- mice.
  • Administered KL via adenovirus or protein; analyzed retinal structure/function (OCT, ERG), neovascularization, and macrophage senescence.
  • Utilized cell models (RAW264.7) and patient samples to assess KL's impact on senescence, HECTD1, and IRS1 ubiquitination.

Main Results:

  • Lower KL levels were observed in proliferative diabetic retinopathy (PDR) patients.
  • KL administration improved retinal structure and function, inhibited senescence in diabetic mice, and reduced neovascular lesions.
  • KL protected macrophages from senescence, downregulated HECTD1, and inhibited HECTD1 binding to IRS1, reducing IRS1 ubiquitination.

Conclusions:

  • Macrophage aging contributes to diabetic retinopathy.
  • KL alleviates DR by reducing retinal macrophage senescence via HECTD1 and IRS1 pathways.
  • KL administration attenuates neovascular lesions by modulating macrophage activation and decreasing VEGFA/FGF2.